Physician profile
Mustafa Rahim
NPI 1831289891
$4,881.87
in general payments reported to CMS, 2019-2025
49 companies · $592 in 2025
The $592 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $615 · 2021: $735 · 2022: $487 · 2023: $645 · 2024: $1,095 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,193 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.36 |
| Education | $138.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $459.25 | 2019-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $367.65 | 2019-2025 | |
| Abbvie INC. | $352.81 | 2021-2025 | |
| Novo Nordisk INC | $269.67 | 2019-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $263.23 | 2021-2025 | Freestyle Libre 2 |
| Avanir Pharmaceuticals, INC. | $207.24 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $178.02 | 2019-2024 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $172.41 | 2021-2024 | |
| Lundbeck LLC | $168.02 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $161.25 | 2019-2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $159.82 | 2021-2024 | Austedo Xr, Ajovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.64 | 2019-2025 | Jardiance, Tradjenta |
| Sunovion Pharmaceuticals INC. | $135.16 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $134.27 | 2023-2025 | Rexulti |
| Travere Therapeutics, INC. | $133.91 | 2023-2024 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $123.87 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.78 | 2020-2022 | |
| Lilly USA, LLC | $87.45 | 2020-2024 | Zepbound, Jardiance, Mounjaro |
| Xeris Pharmaceuticals, INC. | $86.93 | 2021-2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.80 | 2019-2021 | |
| Pfizer INC. | $77.28 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $74.39 | 2021-2025 | Verquvo, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $73.86 | 2023 | Rexulti, Nuedexta |
| Amarin Pharma, INC. | $70.50 | 2019-2020 | |
| Verona Pharma, INC. | $69.85 | 2025 | Ohtuvayre |
| Kyowa Kirin, INC. | $65.48 | 2020-2025 | Crysvita |
| Amgen INC. | $55.66 | 2021-2023 | Repatha, Otezla |
| Tandem Diabetes Care, INC. | $52.07 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.03 | 2022-2025 | Lifevest |
| Dexcom, INC. | $46.96 | 2021-2023 | Dexcom G6 Transmitter |
| Melinta Therapeutics, LLC | $45.72 | 2019 | |
| Aimmune Therapeutics, INC. | $41.51 | 2025 | Vowst |
| Horizon Therapeutics Plc | $41.43 | 2022 | |
| Insulet Corporation | $40.29 | 2024 | Omnipod |
| Neurelis, INC. | $38.63 | 2023 | Valtoco |
| Ferring Pharmaceuticals INC. | $35.57 | 2023 | Rebyota |
| Acadia Pharmaceuticals INC | $25.79 | 2019-2024 | Nuplazid |
| Mylan Specialty L.P. | $23.21 | 2020 | |
| Astellas Pharma US INC | $22.28 | 2024 | Veozah |
| Acorda Therapeutics, INC | $20.27 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.18 | 2024 | Voquezna |
| Optos, INC. | $18.68 | 2021 | |
| Esperion Therapeutics, INC. | $15.52 | 2024 | Nexletol |
| Circassia INC. | $14.08 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.74 | 2023 | Quviviq |
| Ibsa Pharma INC. | $13.48 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $12.82 | 2021 | |
| Baxter Healthcare | $12.12 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mustafa Rahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.